HC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $15.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 211.20% from the company’s current price.

TCRX has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a research note on Tuesday. Wedbush reaffirmed an “outperform” rating and set a $10.00 price target on shares of TScan Therapeutics in a report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock opened at $4.82 on Friday. The company has a 50 day moving average of $5.33 and a 200-day moving average of $6.51. The company has a market cap of $255.32 million, a PE ratio of -4.55 and a beta of 0.79. The company has a current ratio of 9.56, a quick ratio of 7.77 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a 1-year low of $3.73 and a 1-year high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.02. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $1.55 million. As a group, equities research analysts forecast that TScan Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction dated Monday, September 23rd. The stock was purchased at an average cost of $5.29 per share, with a total value of $26,450.00. Following the transaction, the director now owns 45,000 shares in the company, valued at approximately $238,050. The trade was a 12.50 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now directly owns 4,716 shares of the company’s stock, valued at $27,258.48. This represents a 97.22 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have purchased 15,000 shares of company stock worth $82,550. Insiders own 2.76% of the company’s stock.

Institutional Trading of TScan Therapeutics

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in TScan Therapeutics by 1.1% in the first quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after purchasing an additional 20,000 shares during the period. Great Point Partners LLC raised its stake in TScan Therapeutics by 8.0% during the 3rd quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock worth $5,062,000 after buying an additional 75,544 shares during the period. abrdn plc grew its stake in TScan Therapeutics by 27.2% in the third quarter. abrdn plc now owns 371,655 shares of the company’s stock valued at $1,851,000 after acquiring an additional 79,511 shares during the period. Marshall Wace LLP increased its holdings in shares of TScan Therapeutics by 60.8% during the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock valued at $1,799,000 after acquiring an additional 116,316 shares in the last quarter. Finally, Tocqueville Asset Management L.P. acquired a new position in shares of TScan Therapeutics during the first quarter worth approximately $1,685,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.